Glucose metabolism and cardiac hypertrophy

被引:237
|
作者
Kolwicz, Stephen C., Jr. [1 ]
Tian, Rong [1 ]
机构
[1] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Mitochondria & Metab Ctr, Seattle, WA 98109 USA
基金
美国国家卫生研究院;
关键词
Glycolysis; Metabolic flexibility; Foetal metabolic profile; ACTIVATED-RECEPTOR-ALPHA; GLUCAGON-LIKE PEPTIDE-1; FATTY-ACID OXIDATION; PRESSURE-OVERLOAD HYPERTROPHY; PENTOSE-PHOSPHATE PATHWAY; LEFT-VENTRICULAR DYSFUNCTION; CONGESTIVE-HEART-FAILURE; PROPIONYL-L-CARNITINE; FAILING HUMAN HEART; RAT HEARTS;
D O I
10.1093/cvr/cvr071
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The most notable change in the metabolic profile of hypertrophied hearts is an increased reliance on glucose with an overall reduced oxidative metabolism, i.e. a reappearance of the foetal metabolic pattern. In animal models, this change is attributed to the down-regulation of the transcriptional cascades promoting gene expression for fatty acid oxidation and mitochondrial oxidative phosphorylation in adult hearts. Impaired myocardial energetics in cardiac hypertrophy also triggers AMP-activated protein kinase (AMPK), leading to increased glucose uptake and glycolysis. Aside from increased reliance on glucose as an energy source, changes in other glucose metabolism pathways, e. g. the pentose phosphate pathway, the glucosamine biosynthesis pathway, and anaplerosis, are also noted in the hypertrophied hearts. Studies using transgenic mouse models and pharmacological compounds to mimic or counter the switch of substrate preference in cardiac hypertrophy have demonstrated that increased glucose metabolism in adult heart is not harmful and can be beneficial when it provides sufficient fuel for oxidative metabolism. However, improvement in the oxidative capacity and efficiency rather than the selection of the substrate is likely the ultimate goal for metabolic therapies.
引用
收藏
页码:194 / 201
页数:8
相关论文
共 50 条
  • [21] ABNORMAL POLYAMINE METABOLISM IN HYPERTENSIVE CARDIAC-HYPERTROPHY
    SHIMIZU, M
    MASUDA, I
    AIHARA, K
    NAKANO, T
    OGAWA, K
    MIZOKAMI, T
    IRIMAJIRI, O
    TANIGUCHI, I
    OZASA, H
    KAGEYAMA, S
    HAYASHI, S
    ISOGAI, Y
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1988, 52 (10): : 1209 - 1215
  • [22] Cardiac metabolism in hypertrophy and heart failure: implications for therapy
    Siddiqi, N.
    Singh, S.
    Beadle, R.
    Dawson, D.
    Frenneaux, M.
    HEART FAILURE REVIEWS, 2013, 18 (05) : 595 - 606
  • [23] ABNORMAL POLYAMINE METABOLISM IN HYPERTENSIVE CARDIAC-HYPERTROPHY
    SHIMIZU, M
    MASUDA, I
    UTSUNOMIYA, K
    AIHARA, K
    OZASA, H
    TANIGUCHI, I
    KAGEYAMA, S
    ISOGAI, Y
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1986, 50 (08): : 718 - 718
  • [24] Does the lipidic metabolism of myocardium modulate cardiac hypertrophy?
    Planavila, A
    Jové, M
    Cabrero, A
    Carrera, AV
    NEFROLOGIA, 2004, 24 : 29 - 33
  • [25] Cardiac metabolism in hypertrophy and heart failure: implications for therapy
    N. Siddiqi
    S. Singh
    R. Beadle
    D. Dawson
    M. Frenneaux
    Heart Failure Reviews, 2013, 18 : 595 - 606
  • [26] Nitric oxide and impaired energy metabolism in cardiac hypertrophy
    Dai, LJ
    Brookes, PS
    Darley-Usmar, VM
    Anderson, PG
    CIRCULATION, 2001, 104 (17) : 190 - 190
  • [27] PYRIMIDINE NUCLEOTIDE-METABOLISM IN CARDIAC-HYPERTROPHY
    ROSSI, A
    AUSSEDAT, J
    OLIVARES, J
    RAY, A
    VERDYS, M
    EUROPEAN HEART JOURNAL, 1984, 5 : 155 - 162
  • [28] Introduction to special issue on cardiac metabolism in hypertrophy and failure
    William C. Stanley
    Heart Failure Reviews, 2013, 18 : 553 - 553
  • [29] Lean heart: Role of leptin in cardiac hypertrophy and metabolism
    Hall, Michael E.
    Harmancey, Romain
    Stec, David E.
    WORLD JOURNAL OF CARDIOLOGY, 2015, 7 (09): : 511 - 524
  • [30] Hydrogen sulfide improves glucose metabolism and prevents hypertrophy in cardiomyocytes
    Liang, Min
    Jin, Sheng
    Wu, Dong-Dong
    Wang, Ming-Jie
    Zhu, Yi-Chun
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2015, 46 : 114 - 122